These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 25280283)

  • 1. Re: does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer?
    Griebling TL
    J Urol; 2014 Jun; 191(6):1784-5. PubMed ID: 25280283
    [No Abstract]   [Full Text] [Related]  

  • 2. Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer?
    Keating NL; O'Malley AJ; Freedland SJ; Smith MR
    Eur Urol; 2013 Jul; 64(1):159-66. PubMed ID: 22537796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.
    Keating NL; O'Malley AJ; Smith MR
    J Clin Oncol; 2006 Sep; 24(27):4448-56. PubMed ID: 16983113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hormone refractory prostate cancer and the prevention of the adverse effects of the treatment].
    Zgliczyński S; Borówka A
    Endokrynol Pol; 2005; 56(3):223. PubMed ID: 16350713
    [No Abstract]   [Full Text] [Related]  

  • 5. Treating asymptomatic patients with hormone-refractory prostate cancer: hormonal manipulations for the urologist.
    Boudreaux KJ; Chang SS
    BJU Int; 2008 Mar; 101(6):671-4. PubMed ID: 18070172
    [No Abstract]   [Full Text] [Related]  

  • 6. Cardiovascular disease with androgen deprivation: the (forgotten) role of testosterone.
    Aragon-Ching JB
    J Clin Oncol; 2009 Dec; 27(35):e261; author reply e262. PubMed ID: 19884519
    [No Abstract]   [Full Text] [Related]  

  • 7. Development of comorbidities in men with prostate cancer treated with androgen deprivation therapy: an Australian population-based cohort study.
    Ng HS; Koczwara B; Roder D; Vitry A
    Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):403-410. PubMed ID: 29720722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate cancer, osteoporosis and fracture risk.
    Allain TJ
    Gerontology; 2006; 52(2):107-10. PubMed ID: 16508318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.
    Keating NL; O'Malley A; Freedland SJ; Smith MR
    J Natl Cancer Inst; 2012 Oct; 104(19):1518-23. PubMed ID: 23210129
    [No Abstract]   [Full Text] [Related]  

  • 10. Study changes how physicians treat metastatic prostate cancer: intermittent hormone therapy not as effective as continuous hormone therapy, authors say.
    Printz C
    Cancer; 2013 Sep; 119(17):3103-4. PubMed ID: 24037668
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of delayed maximal androgen blockade therapy for patients with advanced prostate cancer who fail to respond to initial androgen deprivation monotherapy.
    Takayanagi A; Masumori N; Hashimoto J; Kyoda Y; Yanase M; Tsukamoto T
    Jpn J Clin Oncol; 2010 Dec; 40(12):1154-8. PubMed ID: 20647233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary androgen deprivation therapy in men with prostate cancer.
    Laufman L
    JAMA; 2009 Jan; 301(1):35; author reply 35. PubMed ID: 19126809
    [No Abstract]   [Full Text] [Related]  

  • 13. Androgen-deprivation therapy and metabolic syndrome in men with prostate cancer.
    Harrington JM; Schwenke DC; Epstein DR; Bailey DE
    Oncol Nurs Forum; 2014 Jan; 41(1):21-9. PubMed ID: 24368236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonates in prostate cancer: where are we and where should we go?
    Saad F
    J Natl Cancer Inst; 2003 Sep; 95(17):1262-3. PubMed ID: 12953073
    [No Abstract]   [Full Text] [Related]  

  • 15. Intermittent androgen deprivation therapy in prostate cancer: is everything so clear?
    Mottet N
    Eur Urol; 2013 Jan; 63(1):121-2; discussion 123-4. PubMed ID: 22921963
    [No Abstract]   [Full Text] [Related]  

  • 16. [Current strategies of intermittent hormone therapy in prostate cancer].
    Kaprin AD; Pavlov AIu; Ivanov SA; Gafanov RA
    Vopr Onkol; 2011; 57(2):260-4. PubMed ID: 21809677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen deprivation therapy for localized and nonmetastatic prostate cancer: too much of a good thing?
    Konijeti R; Kibel AS
    Eur Urol; 2012 Jun; 61(6):1129-30; discussion 1131. PubMed ID: 22445550
    [No Abstract]   [Full Text] [Related]  

  • 18. Current topics and perspectives relating to hormone therapy for prostate cancer.
    Suzuki H; Kamiya N; Imamoto T; Kawamura K; Yano M; Takano M; Utsumi T; Naya Y; Ichikawa T
    Int J Clin Oncol; 2008 Oct; 13(5):401-10. PubMed ID: 18946750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re: Alessandro Sciarra, Per Anders Abrahamsson, Maurizio Brausi, et al. Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials. Eur Urol 2013;64:722-30.
    Tombal B
    Eur Urol; 2014 Apr; 65(4):e56. PubMed ID: 24380648
    [No Abstract]   [Full Text] [Related]  

  • 20. Steroid hormone withdrawal syndromes. Pathophysiology and clinical significance.
    Kelly WK; Slovin S; Scher HI
    Urol Clin North Am; 1997 May; 24(2):421-31. PubMed ID: 9126240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.